Amedisys, Inc. (AMED) Stock Competitors & Peer Comparison
See (AMED) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Care Facilities Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| AMED | $100.99 | +0.01% | 3.3B | 39.30 | $2.57 | N/A |
| HCA | $372.13 | +2.85% | 82.5B | 12.82 | $29.02 | +0.79% |
| SOLV | $81.01 | -1.71% | 14B | 9.92 | $8.17 | N/A |
| THC | $162.06 | +0.43% | 14B | 8.43 | $19.24 | N/A |
| DVA | $192.16 | -0.01% | 12.3B | 18.50 | $10.38 | N/A |
| FMS | $22.03 | +0.46% | 11.8B | 11.59 | $1.90 | +3.94% |
| EHC | $104.01 | +4.18% | 10.3B | 17.82 | $5.84 | +0.71% |
| ENSG | $170.30 | +3.66% | 10B | 27.74 | $6.14 | +0.15% |
| OSH | $39.00 | +0.08% | 9.5B | -17.65 | -$2.21 | N/A |
| UHS | $145.17 | +1.72% | 9.1B | 6.06 | $23.95 | +0.55% |
Stock Comparison
AMED vs HCA Comparison June 2026
AMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMED stands at 3.3B. In comparison, HCA has a market cap of 82.5B. Regarding current trading prices, AMED is priced at $100.99, while HCA trades at $372.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMED currently has a P/E ratio of 39.30, whereas HCA's P/E ratio is 12.82. In terms of profitability, AMED's ROE is +0.09%, compared to HCA's ROE of -1.23%. Regarding short-term risk, AMED is less volatile compared to HCA. This indicates potentially lower risk in terms of short-term price fluctuations for AMED.Check HCA's competition here
AMED vs SOLV Comparison June 2026
AMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMED stands at 3.3B. In comparison, SOLV has a market cap of 14B. Regarding current trading prices, AMED is priced at $100.99, while SOLV trades at $81.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMED currently has a P/E ratio of 39.30, whereas SOLV's P/E ratio is 9.92. In terms of profitability, AMED's ROE is +0.09%, compared to SOLV's ROE of +0.31%. Regarding short-term risk, AMED is less volatile compared to SOLV. This indicates potentially lower risk in terms of short-term price fluctuations for AMED.Check SOLV's competition here
AMED vs THC Comparison June 2026
AMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMED stands at 3.3B. In comparison, THC has a market cap of 14B. Regarding current trading prices, AMED is priced at $100.99, while THC trades at $162.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMED currently has a P/E ratio of 39.30, whereas THC's P/E ratio is 8.43. In terms of profitability, AMED's ROE is +0.09%, compared to THC's ROE of +0.41%. Regarding short-term risk, AMED is less volatile compared to THC. This indicates potentially lower risk in terms of short-term price fluctuations for AMED.Check THC's competition here
AMED vs DVA Comparison June 2026
AMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMED stands at 3.3B. In comparison, DVA has a market cap of 12.3B. Regarding current trading prices, AMED is priced at $100.99, while DVA trades at $192.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMED currently has a P/E ratio of 39.30, whereas DVA's P/E ratio is 18.50. In terms of profitability, AMED's ROE is +0.09%, compared to DVA's ROE of -1.33%. Regarding short-term risk, AMED is less volatile compared to DVA. This indicates potentially lower risk in terms of short-term price fluctuations for AMED.Check DVA's competition here
AMED vs FMS Comparison June 2026
AMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMED stands at 3.3B. In comparison, FMS has a market cap of 11.8B. Regarding current trading prices, AMED is priced at $100.99, while FMS trades at $22.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMED currently has a P/E ratio of 39.30, whereas FMS's P/E ratio is 11.59. In terms of profitability, AMED's ROE is +0.09%, compared to FMS's ROE of +0.07%. Regarding short-term risk, AMED is less volatile compared to FMS. This indicates potentially lower risk in terms of short-term price fluctuations for AMED.Check FMS's competition here
AMED vs EHC Comparison June 2026
AMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMED stands at 3.3B. In comparison, EHC has a market cap of 10.3B. Regarding current trading prices, AMED is priced at $100.99, while EHC trades at $104.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMED currently has a P/E ratio of 39.30, whereas EHC's P/E ratio is 17.82. In terms of profitability, AMED's ROE is +0.09%, compared to EHC's ROE of +0.25%. Regarding short-term risk, AMED is less volatile compared to EHC. This indicates potentially lower risk in terms of short-term price fluctuations for AMED.Check EHC's competition here
AMED vs ENSG Comparison June 2026
AMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMED stands at 3.3B. In comparison, ENSG has a market cap of 10B. Regarding current trading prices, AMED is priced at $100.99, while ENSG trades at $170.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMED currently has a P/E ratio of 39.30, whereas ENSG's P/E ratio is 27.74. In terms of profitability, AMED's ROE is +0.09%, compared to ENSG's ROE of +0.17%. Regarding short-term risk, AMED is less volatile compared to ENSG. This indicates potentially lower risk in terms of short-term price fluctuations for AMED.Check ENSG's competition here
AMED vs OSH Comparison June 2026
AMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMED stands at 3.3B. In comparison, OSH has a market cap of 9.5B. Regarding current trading prices, AMED is priced at $100.99, while OSH trades at $39.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMED currently has a P/E ratio of 39.30, whereas OSH's P/E ratio is -17.65. In terms of profitability, AMED's ROE is +0.09%, compared to OSH's ROE of +4.64%. Regarding short-term risk, AMED is more volatile compared to OSH. This indicates potentially higher risk in terms of short-term price fluctuations for AMED.Check OSH's competition here
AMED vs UHS Comparison June 2026
AMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMED stands at 3.3B. In comparison, UHS has a market cap of 9.1B. Regarding current trading prices, AMED is priced at $100.99, while UHS trades at $145.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMED currently has a P/E ratio of 39.30, whereas UHS's P/E ratio is 6.06. In terms of profitability, AMED's ROE is +0.09%, compared to UHS's ROE of +0.21%. Regarding short-term risk, AMED is less volatile compared to UHS. This indicates potentially lower risk in terms of short-term price fluctuations for AMED.Check UHS's competition here
AMED vs CHE Comparison June 2026
AMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMED stands at 3.3B. In comparison, CHE has a market cap of 5.9B. Regarding current trading prices, AMED is priced at $100.99, while CHE trades at $441.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMED currently has a P/E ratio of 39.30, whereas CHE's P/E ratio is 24.09. In terms of profitability, AMED's ROE is +0.09%, compared to CHE's ROE of +0.25%. Regarding short-term risk, AMED is less volatile compared to CHE. This indicates potentially lower risk in terms of short-term price fluctuations for AMED.Check CHE's competition here
AMED vs LHCG Comparison June 2026
AMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMED stands at 3.3B. In comparison, LHCG has a market cap of 5.3B. Regarding current trading prices, AMED is priced at $100.99, while LHCG trades at $169.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMED currently has a P/E ratio of 39.30, whereas LHCG's P/E ratio is 82.83. In terms of profitability, AMED's ROE is +0.09%, compared to LHCG's ROE of +0.04%. Regarding short-term risk, AMED is less volatile compared to LHCG. This indicates potentially lower risk in terms of short-term price fluctuations for AMED.Check LHCG's competition here
AMED vs MMED Comparison June 2026
AMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMED stands at 3.3B. In comparison, MMED has a market cap of 4B. Regarding current trading prices, AMED is priced at $100.99, while MMED trades at $14.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMED currently has a P/E ratio of 39.30, whereas MMED's P/E ratio is -11.20. In terms of profitability, AMED's ROE is +0.09%, compared to MMED's ROE of -0.09%. Regarding short-term risk, AMED is less volatile compared to MMED. This indicates potentially lower risk in terms of short-term price fluctuations for AMED.Check MMED's competition here
AMED vs OPCH Comparison June 2026
AMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMED stands at 3.3B. In comparison, OPCH has a market cap of 3.2B. Regarding current trading prices, AMED is priced at $100.99, while OPCH trades at $20.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMED currently has a P/E ratio of 39.30, whereas OPCH's P/E ratio is 16.02. In terms of profitability, AMED's ROE is +0.09%, compared to OPCH's ROE of +0.15%. Regarding short-term risk, AMED is less volatile compared to OPCH. This indicates potentially lower risk in terms of short-term price fluctuations for AMED.Check OPCH's competition here
AMED vs NHC Comparison June 2026
AMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMED stands at 3.3B. In comparison, NHC has a market cap of 3B. Regarding current trading prices, AMED is priced at $100.99, while NHC trades at $192.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMED currently has a P/E ratio of 39.30, whereas NHC's P/E ratio is 24.46. In terms of profitability, AMED's ROE is +0.09%, compared to NHC's ROE of +0.12%. Regarding short-term risk, AMED is less volatile compared to NHC. This indicates potentially lower risk in terms of short-term price fluctuations for AMED.Check NHC's competition here
AMED vs BKD Comparison June 2026
AMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMED stands at 3.3B. In comparison, BKD has a market cap of 2.9B. Regarding current trading prices, AMED is priced at $100.99, while BKD trades at $12.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMED currently has a P/E ratio of 39.30, whereas BKD's P/E ratio is -14.17. In terms of profitability, AMED's ROE is +0.09%, compared to BKD's ROE of +401.19%. Regarding short-term risk, AMED is less volatile compared to BKD. This indicates potentially lower risk in terms of short-term price fluctuations for AMED.Check BKD's competition here
AMED vs LFST Comparison June 2026
AMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMED stands at 3.3B. In comparison, LFST has a market cap of 2.9B. Regarding current trading prices, AMED is priced at $100.99, while LFST trades at $7.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMED currently has a P/E ratio of 39.30, whereas LFST's P/E ratio is 123.50. In terms of profitability, AMED's ROE is +0.09%, compared to LFST's ROE of +0.02%. Regarding short-term risk, AMED is less volatile compared to LFST. This indicates potentially lower risk in terms of short-term price fluctuations for AMED.Check LFST's competition here
AMED vs ACHC Comparison June 2026
AMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMED stands at 3.3B. In comparison, ACHC has a market cap of 2.3B. Regarding current trading prices, AMED is priced at $100.99, while ACHC trades at $24.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMED currently has a P/E ratio of 39.30, whereas ACHC's P/E ratio is -2.01. In terms of profitability, AMED's ROE is +0.09%, compared to ACHC's ROE of -0.44%. Regarding short-term risk, AMED is less volatile compared to ACHC. This indicates potentially lower risk in terms of short-term price fluctuations for AMED.Check ACHC's competition here
AMED vs SEM Comparison June 2026
AMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMED stands at 3.3B. In comparison, SEM has a market cap of 2.1B. Regarding current trading prices, AMED is priced at $100.99, while SEM trades at $16.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMED currently has a P/E ratio of 39.30, whereas SEM's P/E ratio is 15.47. In terms of profitability, AMED's ROE is +0.09%, compared to SEM's ROE of +0.08%. Regarding short-term risk, AMED is less volatile compared to SEM. This indicates potentially lower risk in terms of short-term price fluctuations for AMED.Check SEM's competition here
AMED vs ASTH Comparison June 2026
AMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMED stands at 3.3B. In comparison, ASTH has a market cap of 1.9B. Regarding current trading prices, AMED is priced at $100.99, while ASTH trades at $37.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMED currently has a P/E ratio of 39.30, whereas ASTH's P/E ratio is 62.28. In terms of profitability, AMED's ROE is +0.09%, compared to ASTH's ROE of +0.04%. Regarding short-term risk, AMED is less volatile compared to ASTH. This indicates potentially lower risk in terms of short-term price fluctuations for AMED.Check ASTH's competition here
AMED vs MD Comparison June 2026
AMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMED stands at 3.3B. In comparison, MD has a market cap of 1.9B. Regarding current trading prices, AMED is priced at $100.99, while MD trades at $22.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMED currently has a P/E ratio of 39.30, whereas MD's P/E ratio is 10.97. In terms of profitability, AMED's ROE is +0.09%, compared to MD's ROE of +0.20%. Regarding short-term risk, AMED is less volatile compared to MD. This indicates potentially lower risk in terms of short-term price fluctuations for AMED.Check MD's competition here
AMED vs AMEH Comparison June 2026
AMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMED stands at 3.3B. In comparison, AMEH has a market cap of 1.8B. Regarding current trading prices, AMED is priced at $100.99, while AMEH trades at $40.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMED currently has a P/E ratio of 39.30, whereas AMEH's P/E ratio is 39.25. In terms of profitability, AMED's ROE is +0.09%, compared to AMEH's ROE of +0.04%. Regarding short-term risk, AMED is less volatile compared to AMEH. This indicates potentially lower risk in terms of short-term price fluctuations for AMED.Check AMEH's competition here
AMED vs SGRY Comparison June 2026
AMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMED stands at 3.3B. In comparison, SGRY has a market cap of 1.8B. Regarding current trading prices, AMED is priced at $100.99, while SGRY trades at $13.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMED currently has a P/E ratio of 39.30, whereas SGRY's P/E ratio is -23.24. In terms of profitability, AMED's ROE is +0.09%, compared to SGRY's ROE of -0.04%. Regarding short-term risk, AMED is less volatile compared to SGRY. This indicates potentially lower risk in terms of short-term price fluctuations for AMED.Check SGRY's competition here
AMED vs ADUS Comparison June 2026
AMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMED stands at 3.3B. In comparison, ADUS has a market cap of 1.7B. Regarding current trading prices, AMED is priced at $100.99, while ADUS trades at $92.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMED currently has a P/E ratio of 39.30, whereas ADUS's P/E ratio is 16.99. In terms of profitability, AMED's ROE is +0.09%, compared to ADUS's ROE of +0.09%. Regarding short-term risk, AMED is less volatile compared to ADUS. This indicates potentially lower risk in terms of short-term price fluctuations for AMED.Check ADUS's competition here
AMED vs AGL Comparison June 2026
AMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMED stands at 3.3B. In comparison, AGL has a market cap of 1.6B. Regarding current trading prices, AMED is priced at $100.99, while AGL trades at $96.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMED currently has a P/E ratio of 39.30, whereas AGL's P/E ratio is -4.29. In terms of profitability, AMED's ROE is +0.09%, compared to AGL's ROE of -1.46%. Regarding short-term risk, AMED is less volatile compared to AGL. This indicates potentially lower risk in terms of short-term price fluctuations for AMED.Check AGL's competition here
AMED vs AVAH Comparison June 2026
AMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMED stands at 3.3B. In comparison, AVAH has a market cap of 1.5B. Regarding current trading prices, AMED is priced at $100.99, while AVAH trades at $6.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMED currently has a P/E ratio of 39.30, whereas AVAH's P/E ratio is 5.52. In terms of profitability, AMED's ROE is +0.09%, compared to AVAH's ROE of +2.41%. Regarding short-term risk, AMED is less volatile compared to AVAH. This indicates potentially lower risk in terms of short-term price fluctuations for AMED.Check AVAH's competition here
AMED vs HCSG Comparison June 2026
AMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMED stands at 3.3B. In comparison, HCSG has a market cap of 1.4B. Regarding current trading prices, AMED is priced at $100.99, while HCSG trades at $20.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMED currently has a P/E ratio of 39.30, whereas HCSG's P/E ratio is 21.44. In terms of profitability, AMED's ROE is +0.09%, compared to HCSG's ROE of +0.14%. Regarding short-term risk, AMED is less volatile compared to HCSG. This indicates potentially lower risk in terms of short-term price fluctuations for AMED.Check HCSG's competition here
AMED vs ARDT Comparison June 2026
AMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMED stands at 3.3B. In comparison, ARDT has a market cap of 1.2B. Regarding current trading prices, AMED is priced at $100.99, while ARDT trades at $8.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMED currently has a P/E ratio of 39.30, whereas ARDT's P/E ratio is 9.26. In terms of profitability, AMED's ROE is +0.09%, compared to ARDT's ROE of +0.09%. Regarding short-term risk, AMED is less volatile compared to ARDT. This indicates potentially lower risk in terms of short-term price fluctuations for AMED.Check ARDT's competition here
AMED vs BKDT Comparison June 2026
AMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMED stands at 3.3B. In comparison, BKDT has a market cap of 1.2B. Regarding current trading prices, AMED is priced at $100.99, while BKDT trades at $77.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMED currently has a P/E ratio of 39.30, whereas BKDT's P/E ratio is N/A. In terms of profitability, AMED's ROE is +0.09%, compared to BKDT's ROE of +401.19%. Regarding short-term risk, AMED is more volatile compared to BKDT. This indicates potentially higher risk in terms of short-term price fluctuations for AMED.Check BKDT's competition here
AMED vs AMN Comparison June 2026
AMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMED stands at 3.3B. In comparison, AMN has a market cap of 1.2B. Regarding current trading prices, AMED is priced at $100.99, while AMN trades at $31.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMED currently has a P/E ratio of 39.30, whereas AMN's P/E ratio is -36.81. In terms of profitability, AMED's ROE is +0.09%, compared to AMN's ROE of -0.05%. Regarding short-term risk, AMED is less volatile compared to AMN. This indicates potentially lower risk in terms of short-term price fluctuations for AMED.Check AMN's competition here
AMED vs CMPS Comparison June 2026
AMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMED stands at 3.3B. In comparison, CMPS has a market cap of 1.2B. Regarding current trading prices, AMED is priced at $100.99, while CMPS trades at $12.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMED currently has a P/E ratio of 39.30, whereas CMPS's P/E ratio is -3.86. In terms of profitability, AMED's ROE is +0.09%, compared to CMPS's ROE of -1.51%. Regarding short-term risk, AMED is less volatile compared to CMPS. This indicates potentially lower risk in terms of short-term price fluctuations for AMED.Check CMPS's competition here
AMED vs PNTG Comparison June 2026
AMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMED stands at 3.3B. In comparison, PNTG has a market cap of 1.1B. Regarding current trading prices, AMED is priced at $100.99, while PNTG trades at $31.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMED currently has a P/E ratio of 39.30, whereas PNTG's P/E ratio is 36.87. In terms of profitability, AMED's ROE is +0.09%, compared to PNTG's ROE of +0.09%. Regarding short-term risk, AMED is less volatile compared to PNTG. This indicates potentially lower risk in terms of short-term price fluctuations for AMED.Check PNTG's competition here
AMED vs INNV Comparison June 2026
AMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMED stands at 3.3B. In comparison, INNV has a market cap of 990.9M. Regarding current trading prices, AMED is priced at $100.99, while INNV trades at $7.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMED currently has a P/E ratio of 39.30, whereas INNV's P/E ratio is -91.25. In terms of profitability, AMED's ROE is +0.09%, compared to INNV's ROE of -0.09%. Regarding short-term risk, AMED is less volatile compared to INNV. This indicates potentially lower risk in terms of short-term price fluctuations for AMED.Check INNV's competition here
AMED vs USPH Comparison June 2026
AMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMED stands at 3.3B. In comparison, USPH has a market cap of 966.4M. Regarding current trading prices, AMED is priced at $100.99, while USPH trades at $63.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMED currently has a P/E ratio of 39.30, whereas USPH's P/E ratio is 127.00. In terms of profitability, AMED's ROE is +0.09%, compared to USPH's ROE of +0.00%. Regarding short-term risk, AMED is less volatile compared to USPH. This indicates potentially lower risk in terms of short-term price fluctuations for AMED.Check USPH's competition here
AMED vs TALK Comparison June 2026
AMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMED stands at 3.3B. In comparison, TALK has a market cap of 874.4M. Regarding current trading prices, AMED is priced at $100.99, while TALK trades at $5.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMED currently has a P/E ratio of 39.30, whereas TALK's P/E ratio is 130.50. In terms of profitability, AMED's ROE is +0.09%, compared to TALK's ROE of +0.01%. Regarding short-term risk, AMED is less volatile compared to TALK. This indicates potentially lower risk in terms of short-term price fluctuations for AMED.Check TALK's competition here
AMED vs FSHCX Comparison June 2026
AMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMED stands at 3.3B. In comparison, FSHCX has a market cap of 806.7M. Regarding current trading prices, AMED is priced at $100.99, while FSHCX trades at $109.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMED currently has a P/E ratio of 39.30, whereas FSHCX's P/E ratio is N/A. In terms of profitability, AMED's ROE is +0.09%, compared to FSHCX's ROE of N/A. Regarding short-term risk, AMED is more volatile compared to FSHCX. This indicates potentially higher risk in terms of short-term price fluctuations for AMED.Check FSHCX's competition here
AMED vs EHAB Comparison June 2026
AMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMED stands at 3.3B. In comparison, EHAB has a market cap of 706.9M. Regarding current trading prices, AMED is priced at $100.99, while EHAB trades at $13.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMED currently has a P/E ratio of 39.30, whereas EHAB's P/E ratio is -197.14. In terms of profitability, AMED's ROE is +0.09%, compared to EHAB's ROE of -0.01%. Regarding short-term risk, AMED is less volatile compared to EHAB. This indicates potentially lower risk in terms of short-term price fluctuations for AMED.Check EHAB's competition here
AMED vs SNDA Comparison June 2026
AMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMED stands at 3.3B. In comparison, SNDA has a market cap of 687.2M. Regarding current trading prices, AMED is priced at $100.99, while SNDA trades at $34.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMED currently has a P/E ratio of 39.30, whereas SNDA's P/E ratio is -5.88. In terms of profitability, AMED's ROE is +0.09%, compared to SNDA's ROE of -0.35%. Regarding short-term risk, AMED is less volatile compared to SNDA. This indicates potentially lower risk in terms of short-term price fluctuations for AMED.Check SNDA's competition here
AMED vs GMRS Comparison June 2026
AMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMED stands at 3.3B. In comparison, GMRS has a market cap of 498.3M. Regarding current trading prices, AMED is priced at $100.99, while GMRS trades at $10.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMED currently has a P/E ratio of 39.30, whereas GMRS's P/E ratio is 5.66. In terms of profitability, AMED's ROE is +0.09%, compared to GMRS's ROE of N/A. Regarding short-term risk, AMED is less volatile compared to GMRS. This indicates potentially lower risk in terms of short-term price fluctuations for AMED.Check GMRS's competition here
AMED vs TOI Comparison June 2026
AMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMED stands at 3.3B. In comparison, TOI has a market cap of 486.9M. Regarding current trading prices, AMED is priced at $100.99, while TOI trades at $4.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMED currently has a P/E ratio of 39.30, whereas TOI's P/E ratio is -13.91. In terms of profitability, AMED's ROE is +0.09%, compared to TOI's ROE of +3.27%. Regarding short-term risk, AMED is less volatile compared to TOI. This indicates potentially lower risk in terms of short-term price fluctuations for AMED.Check TOI's competition here
AMED vs MCTA Comparison June 2026
AMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMED stands at 3.3B. In comparison, MCTA has a market cap of 445.6M. Regarding current trading prices, AMED is priced at $100.99, while MCTA trades at $29.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMED currently has a P/E ratio of 39.30, whereas MCTA's P/E ratio is 419.36. In terms of profitability, AMED's ROE is +0.09%, compared to MCTA's ROE of -2.33%. Regarding short-term risk, AMED is more volatile compared to MCTA. This indicates potentially higher risk in terms of short-term price fluctuations for AMED.Check MCTA's competition here
AMED vs CCRN Comparison June 2026
AMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMED stands at 3.3B. In comparison, CCRN has a market cap of 426.1M. Regarding current trading prices, AMED is priced at $100.99, while CCRN trades at $13.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMED currently has a P/E ratio of 39.30, whereas CCRN's P/E ratio is -4.32. In terms of profitability, AMED's ROE is +0.09%, compared to CCRN's ROE of -0.27%. Regarding short-term risk, AMED is less volatile compared to CCRN. This indicates potentially lower risk in terms of short-term price fluctuations for AMED.Check CCRN's competition here
AMED vs CYH Comparison June 2026
AMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMED stands at 3.3B. In comparison, CYH has a market cap of 386.1M. Regarding current trading prices, AMED is priced at $100.99, while CYH trades at $2.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMED currently has a P/E ratio of 39.30, whereas CYH's P/E ratio is 0.80. In terms of profitability, AMED's ROE is +0.09%, compared to CYH's ROE of +0.06%. Regarding short-term risk, AMED is less volatile compared to CYH. This indicates potentially lower risk in terms of short-term price fluctuations for AMED.Check CYH's competition here
AMED vs AIRS Comparison June 2026
AMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMED stands at 3.3B. In comparison, AIRS has a market cap of 360.5M. Regarding current trading prices, AMED is priced at $100.99, while AIRS trades at $5.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMED currently has a P/E ratio of 39.30, whereas AIRS's P/E ratio is -30.06. In terms of profitability, AMED's ROE is +0.09%, compared to AIRS's ROE of -0.12%. Regarding short-term risk, AMED is less volatile compared to AIRS. This indicates potentially lower risk in terms of short-term price fluctuations for AMED.Check AIRS's competition here
AMED vs AONC Comparison June 2026
AMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMED stands at 3.3B. In comparison, AONC has a market cap of 351M. Regarding current trading prices, AMED is priced at $100.99, while AONC trades at $12.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMED currently has a P/E ratio of 39.30, whereas AONC's P/E ratio is -13.48. In terms of profitability, AMED's ROE is +0.09%, compared to AONC's ROE of +0.06%. Regarding short-term risk, AMED is more volatile compared to AONC. This indicates potentially higher risk in terms of short-term price fluctuations for AMED.Check AONC's competition here
AMED vs AUNA Comparison June 2026
AMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMED stands at 3.3B. In comparison, AUNA has a market cap of 327.2M. Regarding current trading prices, AMED is priced at $100.99, while AUNA trades at $4.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMED currently has a P/E ratio of 39.30, whereas AUNA's P/E ratio is 16.37. In terms of profitability, AMED's ROE is +0.09%, compared to AUNA's ROE of +0.04%. Regarding short-term risk, AMED is less volatile compared to AUNA. This indicates potentially lower risk in terms of short-term price fluctuations for AMED.Check AUNA's competition here
AMED vs CSU Comparison June 2026
AMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMED stands at 3.3B. In comparison, CSU has a market cap of 223.7M. Regarding current trading prices, AMED is priced at $100.99, while CSU trades at $33.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMED currently has a P/E ratio of 39.30, whereas CSU's P/E ratio is 0.67. In terms of profitability, AMED's ROE is +0.09%, compared to CSU's ROE of -0.51%. Regarding short-term risk, AMED is less volatile compared to CSU. This indicates potentially lower risk in terms of short-term price fluctuations for AMED.Check CSU's competition here
AMED vs JYNT Comparison June 2026
AMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMED stands at 3.3B. In comparison, JYNT has a market cap of 118.2M. Regarding current trading prices, AMED is priced at $100.99, while JYNT trades at $8.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMED currently has a P/E ratio of 39.30, whereas JYNT's P/E ratio is 92.11. In terms of profitability, AMED's ROE is +0.09%, compared to JYNT's ROE of +0.17%. Regarding short-term risk, AMED is less volatile compared to JYNT. This indicates potentially lower risk in terms of short-term price fluctuations for AMED.Check JYNT's competition here
AMED vs NAKAW Comparison June 2026
AMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMED stands at 3.3B. In comparison, NAKAW has a market cap of 116.4M. Regarding current trading prices, AMED is priced at $100.99, while NAKAW trades at $15.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMED currently has a P/E ratio of 39.30, whereas NAKAW's P/E ratio is N/A. In terms of profitability, AMED's ROE is +0.09%, compared to NAKAW's ROE of -0.85%. Regarding short-term risk, AMED is less volatile compared to NAKAW. This indicates potentially lower risk in terms of short-term price fluctuations for AMED.Check NAKAW's competition here
AMED vs BTMD Comparison June 2026
AMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMED stands at 3.3B. In comparison, BTMD has a market cap of 103.2M. Regarding current trading prices, AMED is priced at $100.99, while BTMD trades at $2.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMED currently has a P/E ratio of 39.30, whereas BTMD's P/E ratio is 5.44. In terms of profitability, AMED's ROE is +0.09%, compared to BTMD's ROE of -0.23%. Regarding short-term risk, AMED is less volatile compared to BTMD. This indicates potentially lower risk in terms of short-term price fluctuations for AMED.Check BTMD's competition here
AMED vs FVE Comparison June 2026
AMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMED stands at 3.3B. In comparison, FVE has a market cap of 98.4M. Regarding current trading prices, AMED is priced at $100.99, while FVE trades at $2.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMED currently has a P/E ratio of 39.30, whereas FVE's P/E ratio is -5.64. In terms of profitability, AMED's ROE is +0.09%, compared to FVE's ROE of -0.15%. Regarding short-term risk, AMED is less volatile compared to FVE. This indicates potentially lower risk in terms of short-term price fluctuations for AMED.Check FVE's competition here
AMED vs KDLYW Comparison June 2026
AMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMED stands at 3.3B. In comparison, KDLYW has a market cap of 96.5M. Regarding current trading prices, AMED is priced at $100.99, while KDLYW trades at $18.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMED currently has a P/E ratio of 39.30, whereas KDLYW's P/E ratio is N/A. In terms of profitability, AMED's ROE is +0.09%, compared to KDLYW's ROE of -0.85%. Regarding short-term risk, AMED is less volatile compared to KDLYW. This indicates potentially lower risk in terms of short-term price fluctuations for AMED.Check KDLYW's competition here
AMED vs DCGO Comparison June 2026
AMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMED stands at 3.3B. In comparison, DCGO has a market cap of 55.2M. Regarding current trading prices, AMED is priced at $100.99, while DCGO trades at $0.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMED currently has a P/E ratio of 39.30, whereas DCGO's P/E ratio is -0.29. In terms of profitability, AMED's ROE is +0.09%, compared to DCGO's ROE of -0.89%. Regarding short-term risk, AMED is less volatile compared to DCGO. This indicates potentially lower risk in terms of short-term price fluctuations for AMED.Check DCGO's competition here
AMED vs ALR Comparison June 2026
AMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMED stands at 3.3B. In comparison, ALR has a market cap of 44.2M. Regarding current trading prices, AMED is priced at $100.99, while ALR trades at $1.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMED currently has a P/E ratio of 39.30, whereas ALR's P/E ratio is -1.11. In terms of profitability, AMED's ROE is +0.09%, compared to ALR's ROE of -0.15%. Regarding short-term risk, AMED is less volatile compared to ALR. This indicates potentially lower risk in terms of short-term price fluctuations for AMED.Check ALR's competition here
AMED vs PIII Comparison June 2026
AMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMED stands at 3.3B. In comparison, PIII has a market cap of 38.1M. Regarding current trading prices, AMED is priced at $100.99, while PIII trades at $11.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMED currently has a P/E ratio of 39.30, whereas PIII's P/E ratio is -0.30. In terms of profitability, AMED's ROE is +0.09%, compared to PIII's ROE of +1.85%. Regarding short-term risk, AMED is less volatile compared to PIII. This indicates potentially lower risk in terms of short-term price fluctuations for AMED.Check PIII's competition here
AMED vs IMAC Comparison June 2026
AMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMED stands at 3.3B. In comparison, IMAC has a market cap of 33.1M. Regarding current trading prices, AMED is priced at $100.99, while IMAC trades at $1.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMED currently has a P/E ratio of 39.30, whereas IMAC's P/E ratio is -2.27. In terms of profitability, AMED's ROE is +0.09%, compared to IMAC's ROE of +1183.61%. Regarding short-term risk, AMED is less volatile compared to IMAC. This indicates potentially lower risk in terms of short-term price fluctuations for AMED.Check IMAC's competition here
AMED vs CCEL Comparison June 2026
AMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMED stands at 3.3B. In comparison, CCEL has a market cap of 27.8M. Regarding current trading prices, AMED is priced at $100.99, while CCEL trades at $3.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMED currently has a P/E ratio of 39.30, whereas CCEL's P/E ratio is -10.78. In terms of profitability, AMED's ROE is +0.09%, compared to CCEL's ROE of +0.16%. Regarding short-term risk, AMED is more volatile compared to CCEL. This indicates potentially higher risk in terms of short-term price fluctuations for AMED.Check CCEL's competition here
AMED vs CANO-WT Comparison June 2026
AMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMED stands at 3.3B. In comparison, CANO-WT has a market cap of 19.3M. Regarding current trading prices, AMED is priced at $100.99, while CANO-WT trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMED currently has a P/E ratio of 39.30, whereas CANO-WT's P/E ratio is N/A. In terms of profitability, AMED's ROE is +0.09%, compared to CANO-WT's ROE of -1.49%. Regarding short-term risk, AMED is less volatile compared to CANO-WT. This indicates potentially lower risk in terms of short-term price fluctuations for AMED.Check CANO-WT's competition here
AMED vs AIH Comparison June 2026
AMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMED stands at 3.3B. In comparison, AIH has a market cap of 15.9M. Regarding current trading prices, AMED is priced at $100.99, while AIH trades at $0.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMED currently has a P/E ratio of 39.30, whereas AIH's P/E ratio is -2.78. In terms of profitability, AMED's ROE is +0.09%, compared to AIH's ROE of +1.16%. Regarding short-term risk, AMED is less volatile compared to AIH. This indicates potentially lower risk in terms of short-term price fluctuations for AMED.Check AIH's competition here
AMED vs CANO Comparison June 2026
AMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMED stands at 3.3B. In comparison, CANO has a market cap of 12.4M. Regarding current trading prices, AMED is priced at $100.99, while CANO trades at $2.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMED currently has a P/E ratio of 39.30, whereas CANO's P/E ratio is -0.01. In terms of profitability, AMED's ROE is +0.09%, compared to CANO's ROE of -1.49%. Regarding short-term risk, AMED is less volatile compared to CANO. This indicates potentially lower risk in terms of short-term price fluctuations for AMED.Check CANO's competition here
AMED vs FTRP Comparison June 2026
AMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMED stands at 3.3B. In comparison, FTRP has a market cap of 9.8M. Regarding current trading prices, AMED is priced at $100.99, while FTRP trades at $0.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMED currently has a P/E ratio of 39.30, whereas FTRP's P/E ratio is -1.22. In terms of profitability, AMED's ROE is +0.09%, compared to FTRP's ROE of -0.62%. Regarding short-term risk, AMED is less volatile compared to FTRP. This indicates potentially lower risk in terms of short-term price fluctuations for AMED.Check FTRP's competition here
AMED vs AMS Comparison June 2026
AMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMED stands at 3.3B. In comparison, AMS has a market cap of 8.7M. Regarding current trading prices, AMED is priced at $100.99, while AMS trades at $1.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMED currently has a P/E ratio of 39.30, whereas AMS's P/E ratio is -6.00. In terms of profitability, AMED's ROE is +0.09%, compared to AMS's ROE of -0.06%. Regarding short-term risk, AMED is less volatile compared to AMS. This indicates potentially lower risk in terms of short-term price fluctuations for AMED.Check AMS's competition here
AMED vs MODV Comparison June 2026
AMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMED stands at 3.3B. In comparison, MODV has a market cap of 6.2M. Regarding current trading prices, AMED is priced at $100.99, while MODV trades at $0.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMED currently has a P/E ratio of 39.30, whereas MODV's P/E ratio is -0.03. In terms of profitability, AMED's ROE is +0.09%, compared to MODV's ROE of +1.84%. Regarding short-term risk, AMED is more volatile compared to MODV. This indicates potentially higher risk in terms of short-term price fluctuations for AMED.Check MODV's competition here
AMED vs GBNH Comparison June 2026
AMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMED stands at 3.3B. In comparison, GBNH has a market cap of 5.5M. Regarding current trading prices, AMED is priced at $100.99, while GBNH trades at $0.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMED currently has a P/E ratio of 39.30, whereas GBNH's P/E ratio is -0.06. In terms of profitability, AMED's ROE is +0.09%, compared to GBNH's ROE of +15.74%. Regarding short-term risk, AMED is less volatile compared to GBNH. This indicates potentially lower risk in terms of short-term price fluctuations for AMED.Check GBNH's competition here
AMED vs SYRA Comparison June 2026
AMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMED stands at 3.3B. In comparison, SYRA has a market cap of 5.4M. Regarding current trading prices, AMED is priced at $100.99, while SYRA trades at $0.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMED currently has a P/E ratio of 39.30, whereas SYRA's P/E ratio is -23.75. In terms of profitability, AMED's ROE is +0.09%, compared to SYRA's ROE of -0.08%. Regarding short-term risk, AMED is less volatile compared to SYRA. This indicates potentially lower risk in terms of short-term price fluctuations for AMED.Check SYRA's competition here
AMED vs RHE Comparison June 2026
AMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMED stands at 3.3B. In comparison, RHE has a market cap of 5.2M. Regarding current trading prices, AMED is priced at $100.99, while RHE trades at $2.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMED currently has a P/E ratio of 39.30, whereas RHE's P/E ratio is -1.79. In terms of profitability, AMED's ROE is +0.09%, compared to RHE's ROE of -0.36%. Regarding short-term risk, AMED is less volatile compared to RHE. This indicates potentially lower risk in terms of short-term price fluctuations for AMED.Check RHE's competition here
AMED vs RHE-PA Comparison June 2026
AMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMED stands at 3.3B. In comparison, RHE-PA has a market cap of 5.2M. Regarding current trading prices, AMED is priced at $100.99, while RHE-PA trades at $0.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMED currently has a P/E ratio of 39.30, whereas RHE-PA's P/E ratio is -0.09. In terms of profitability, AMED's ROE is +0.09%, compared to RHE-PA's ROE of +2.11%. Regarding short-term risk, AMED is less volatile compared to RHE-PA. This indicates potentially lower risk in terms of short-term price fluctuations for AMED.Check RHE-PA's competition here
AMED vs TOIIW Comparison June 2026
AMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMED stands at 3.3B. In comparison, TOIIW has a market cap of 5M. Regarding current trading prices, AMED is priced at $100.99, while TOIIW trades at $0.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMED currently has a P/E ratio of 39.30, whereas TOIIW's P/E ratio is N/A. In terms of profitability, AMED's ROE is +0.09%, compared to TOIIW's ROE of +3.27%. Regarding short-term risk, AMED is less volatile compared to TOIIW. This indicates potentially lower risk in terms of short-term price fluctuations for AMED.Check TOIIW's competition here
AMED vs ATIP Comparison June 2026
AMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMED stands at 3.3B. In comparison, ATIP has a market cap of 3M. Regarding current trading prices, AMED is priced at $100.99, while ATIP trades at $0.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMED currently has a P/E ratio of 39.30, whereas ATIP's P/E ratio is -0.03. In terms of profitability, AMED's ROE is +0.09%, compared to ATIP's ROE of +2.05%. Regarding short-term risk, AMED is less volatile compared to ATIP. This indicates potentially lower risk in terms of short-term price fluctuations for AMED.Check ATIP's competition here
AMED vs IMACW Comparison June 2026
AMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMED stands at 3.3B. In comparison, IMACW has a market cap of 1.7M. Regarding current trading prices, AMED is priced at $100.99, while IMACW trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMED currently has a P/E ratio of 39.30, whereas IMACW's P/E ratio is N/A. In terms of profitability, AMED's ROE is +0.09%, compared to IMACW's ROE of +1.05%. Regarding short-term risk, AMED is less volatile compared to IMACW. This indicates potentially lower risk in terms of short-term price fluctuations for AMED.Check IMACW's competition here
AMED vs CCM Comparison June 2026
AMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMED stands at 3.3B. In comparison, CCM has a market cap of 685.8K. Regarding current trading prices, AMED is priced at $100.99, while CCM trades at $4.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMED currently has a P/E ratio of 39.30, whereas CCM's P/E ratio is -1.50. In terms of profitability, AMED's ROE is +0.09%, compared to CCM's ROE of +0.07%. Regarding short-term risk, AMED is less volatile compared to CCM. This indicates potentially lower risk in terms of short-term price fluctuations for AMED.Check CCM's competition here
AMED vs MNDR Comparison June 2026
AMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMED stands at 3.3B. In comparison, MNDR has a market cap of 620K. Regarding current trading prices, AMED is priced at $100.99, while MNDR trades at $0.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMED currently has a P/E ratio of 39.30, whereas MNDR's P/E ratio is -0.29. In terms of profitability, AMED's ROE is +0.09%, compared to MNDR's ROE of -0.46%. Regarding short-term risk, AMED is less volatile compared to MNDR. This indicates potentially lower risk in terms of short-term price fluctuations for AMED.Check MNDR's competition here
AMED vs TALKW Comparison June 2026
AMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMED stands at 3.3B. In comparison, TALKW has a market cap of 435.5K. Regarding current trading prices, AMED is priced at $100.99, while TALKW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMED currently has a P/E ratio of 39.30, whereas TALKW's P/E ratio is N/A. In terms of profitability, AMED's ROE is +0.09%, compared to TALKW's ROE of +0.01%. Regarding short-term risk, AMED is less volatile compared to TALKW. This indicates potentially lower risk in terms of short-term price fluctuations for AMED.Check TALKW's competition here
AMED vs NVOS Comparison June 2026
AMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMED stands at 3.3B. In comparison, NVOS has a market cap of 394.6K. Regarding current trading prices, AMED is priced at $100.99, while NVOS trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMED currently has a P/E ratio of 39.30, whereas NVOS's P/E ratio is -0.02. In terms of profitability, AMED's ROE is +0.09%, compared to NVOS's ROE of -0.81%. Regarding short-term risk, AMED is less volatile compared to NVOS. This indicates potentially lower risk in terms of short-term price fluctuations for AMED.Check NVOS's competition here
AMED vs NIVF Comparison June 2026
AMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMED stands at 3.3B. In comparison, NIVF has a market cap of 352.3K. Regarding current trading prices, AMED is priced at $100.99, while NIVF trades at $0.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMED currently has a P/E ratio of 39.30, whereas NIVF's P/E ratio is 0.02. In terms of profitability, AMED's ROE is +0.09%, compared to NIVF's ROE of +0.33%. Regarding short-term risk, AMED is less volatile compared to NIVF. This indicates potentially lower risk in terms of short-term price fluctuations for AMED.Check NIVF's competition here
AMED vs BACK Comparison June 2026
AMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMED stands at 3.3B. In comparison, BACK has a market cap of 162.8K. Regarding current trading prices, AMED is priced at $100.99, while BACK trades at $0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMED currently has a P/E ratio of 39.30, whereas BACK's P/E ratio is -0.01. In terms of profitability, AMED's ROE is +0.09%, compared to BACK's ROE of +1.05%. Regarding short-term risk, AMED is less volatile compared to BACK. This indicates potentially lower risk in terms of short-term price fluctuations for AMED.Check BACK's competition here
AMED vs PIIIW Comparison June 2026
AMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMED stands at 3.3B. In comparison, PIIIW has a market cap of 55.6K. Regarding current trading prices, AMED is priced at $100.99, while PIIIW trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMED currently has a P/E ratio of 39.30, whereas PIIIW's P/E ratio is -0.01. In terms of profitability, AMED's ROE is +0.09%, compared to PIIIW's ROE of +1.85%. Regarding short-term risk, AMED is less volatile compared to PIIIW. This indicates potentially lower risk in terms of short-term price fluctuations for AMED.Check PIIIW's competition here
AMED vs NIVFW Comparison June 2026
AMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMED stands at 3.3B. In comparison, NIVFW has a market cap of 45.5K. Regarding current trading prices, AMED is priced at $100.99, while NIVFW trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMED currently has a P/E ratio of 39.30, whereas NIVFW's P/E ratio is N/A. In terms of profitability, AMED's ROE is +0.09%, compared to NIVFW's ROE of +0.33%. Regarding short-term risk, AMED is less volatile compared to NIVFW. This indicates potentially lower risk in terms of short-term price fluctuations for AMED.Check NIVFW's competition here
AMED vs IONM Comparison June 2026
AMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMED stands at 3.3B. In comparison, IONM has a market cap of 313. Regarding current trading prices, AMED is priced at $100.99, while IONM trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMED currently has a P/E ratio of 39.30, whereas IONM's P/E ratio is N/A. In terms of profitability, AMED's ROE is +0.09%, compared to IONM's ROE of +5.28%. Regarding short-term risk, AMED is less volatile compared to IONM. This indicates potentially lower risk in terms of short-term price fluctuations for AMED.Check IONM's competition here
AMED vs ATIP-WT Comparison June 2026
AMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMED stands at 3.3B. In comparison, ATIP-WT has a market cap of 0. Regarding current trading prices, AMED is priced at $100.99, while ATIP-WT trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMED currently has a P/E ratio of 39.30, whereas ATIP-WT's P/E ratio is N/A. In terms of profitability, AMED's ROE is +0.09%, compared to ATIP-WT's ROE of +2.05%. Regarding short-term risk, AMED is less volatile compared to ATIP-WT. This indicates potentially lower risk in terms of short-term price fluctuations for AMED.Check ATIP-WT's competition here
AMED vs KND Comparison June 2026
AMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMED stands at 3.3B. In comparison, KND has a market cap of 0. Regarding current trading prices, AMED is priced at $100.99, while KND trades at $9.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMED currently has a P/E ratio of 39.30, whereas KND's P/E ratio is N/A. In terms of profitability, AMED's ROE is +0.09%, compared to KND's ROE of -0.53%. Regarding short-term risk, AMED is less volatile compared to KND. This indicates potentially lower risk in terms of short-term price fluctuations for AMED.Check KND's competition here
AMED vs TLMD Comparison June 2026
AMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMED stands at 3.3B. In comparison, TLMD has a market cap of 0. Regarding current trading prices, AMED is priced at $100.99, while TLMD trades at $3.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMED currently has a P/E ratio of 39.30, whereas TLMD's P/E ratio is -1.60. In terms of profitability, AMED's ROE is +0.09%, compared to TLMD's ROE of -0.46%. Regarding short-term risk, AMED is less volatile compared to TLMD. This indicates potentially lower risk in terms of short-term price fluctuations for AMED.Check TLMD's competition here
AMED vs SLHGP Comparison June 2026
AMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMED stands at 3.3B. In comparison, SLHGP has a market cap of 0. Regarding current trading prices, AMED is priced at $100.99, while SLHGP trades at $12.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMED currently has a P/E ratio of 39.30, whereas SLHGP's P/E ratio is -30.38. In terms of profitability, AMED's ROE is +0.09%, compared to SLHGP's ROE of -0.48%. Regarding short-term risk, AMED is more volatile compared to SLHGP. This indicates potentially higher risk in terms of short-term price fluctuations for AMED.Check SLHGP's competition here
AMED vs SLHG Comparison June 2026
AMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMED stands at 3.3B. In comparison, SLHG has a market cap of 0. Regarding current trading prices, AMED is priced at $100.99, while SLHG trades at $0.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMED currently has a P/E ratio of 39.30, whereas SLHG's P/E ratio is -1.48. In terms of profitability, AMED's ROE is +0.09%, compared to SLHG's ROE of N/A. Regarding short-term risk, AMED is less volatile compared to SLHG. This indicates potentially lower risk in terms of short-term price fluctuations for AMED.Check SLHG's competition here
AMED vs AFAM Comparison June 2026
AMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMED stands at 3.3B. In comparison, AFAM has a market cap of 0. Regarding current trading prices, AMED is priced at $100.99, while AFAM trades at $56.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMED currently has a P/E ratio of 39.30, whereas AFAM's P/E ratio is N/A. In terms of profitability, AMED's ROE is +0.09%, compared to AFAM's ROE of +0.06%. Regarding short-term risk, AMED is less volatile compared to AFAM. This indicates potentially lower risk in terms of short-term price fluctuations for AMED.Check AFAM's competition here
AMED vs TLMDW Comparison June 2026
AMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMED stands at 3.3B. In comparison, TLMDW has a market cap of 0. Regarding current trading prices, AMED is priced at $100.99, while TLMDW trades at $0.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMED currently has a P/E ratio of 39.30, whereas TLMDW's P/E ratio is N/A. In terms of profitability, AMED's ROE is +0.09%, compared to TLMDW's ROE of -0.46%. Regarding short-term risk, AMED is less volatile compared to TLMDW. This indicates potentially lower risk in terms of short-term price fluctuations for AMED.Check TLMDW's competition here
AMED vs HNGR Comparison June 2026
AMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMED stands at 3.3B. In comparison, HNGR has a market cap of 0. Regarding current trading prices, AMED is priced at $100.99, while HNGR trades at $18.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMED currently has a P/E ratio of 39.30, whereas HNGR's P/E ratio is 19.71. In terms of profitability, AMED's ROE is +0.09%, compared to HNGR's ROE of +0.52%. Regarding short-term risk, AMED is less volatile compared to HNGR. This indicates potentially lower risk in terms of short-term price fluctuations for AMED.Check HNGR's competition here
AMED vs DVCR Comparison June 2026
AMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMED stands at 3.3B. In comparison, DVCR has a market cap of 0. Regarding current trading prices, AMED is priced at $100.99, while DVCR trades at $10.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMED currently has a P/E ratio of 39.30, whereas DVCR's P/E ratio is 28.34. In terms of profitability, AMED's ROE is +0.09%, compared to DVCR's ROE of -0.15%. Regarding short-term risk, AMED is less volatile compared to DVCR. This indicates potentially lower risk in terms of short-term price fluctuations for AMED.Check DVCR's competition here
AMED vs NFH Comparison June 2026
AMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMED stands at 3.3B. In comparison, NFH has a market cap of 0. Regarding current trading prices, AMED is priced at $100.99, while NFH trades at $11.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMED currently has a P/E ratio of 39.30, whereas NFH's P/E ratio is -19.75. In terms of profitability, AMED's ROE is +0.09%, compared to NFH's ROE of -0.06%. Regarding short-term risk, AMED is less volatile compared to NFH. This indicates potentially lower risk in terms of short-term price fluctuations for AMED.Check NFH's competition here
AMED vs TVTY Comparison June 2026
AMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMED stands at 3.3B. In comparison, TVTY has a market cap of 0. Regarding current trading prices, AMED is priced at $100.99, while TVTY trades at $32.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMED currently has a P/E ratio of 39.30, whereas TVTY's P/E ratio is 19.06. In terms of profitability, AMED's ROE is +0.09%, compared to TVTY's ROE of +1.75%. Regarding short-term risk, AMED is more volatile compared to TVTY. This indicates potentially higher risk in terms of short-term price fluctuations for AMED.Check TVTY's competition here
AMED vs DCGOW Comparison June 2026
AMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMED stands at 3.3B. In comparison, DCGOW has a market cap of 0. Regarding current trading prices, AMED is priced at $100.99, while DCGOW trades at $1.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMED currently has a P/E ratio of 39.30, whereas DCGOW's P/E ratio is N/A. In terms of profitability, AMED's ROE is +0.09%, compared to DCGOW's ROE of -0.89%. Regarding short-term risk, AMED is less volatile compared to DCGOW. This indicates potentially lower risk in terms of short-term price fluctuations for AMED.Check DCGOW's competition here